Eli Lilly became the first pharmaceutical company valued at more than $1 trillion, propelled by a 47.67% increase in second-quarter revenue and investor enthusiasm for weight-loss and diabetes drugs including retatrutide and orforglipron. Patients in a Phase 3 retatrutide trial lost an average of 28.3% of their body weight. Lilly raised its 2026 revenue guidance to $85 billion-$87 billion, while earnings are forecast to grow about 16.6% annually. CoinCodex projects Eli Lilly shares could exceed $2,000 by August 2027, implying roughly 75% upside.